NASDAQ:CARA - Cara Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $19.06 -0.20 (-1.04 %) (As of 07/22/2018 03:58 PM ET)Previous Close$19.06Today's Range$18.68 - $19.389052-Week Range$11.11 - $22.29Volume915,775 shsAverage Volume1.57 million shsMarket Capitalization$623.26 millionP/E Ratio-10.25Dividend YieldN/ABeta3.01 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. Receive CARA News and Ratings via Email Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:CARA CUSIPN/A Webwww.caratherapeutics.com Phone203-406-3700 Debt Debt-to-Equity RatioN/A Current Ratio11.47 Quick Ratio11.47 Price-To-Earnings Trailing P/E Ratio-10.25 Forward P/E Ratio-8.78 P/E GrowthN/A Sales & Book Value Annual Sales$910,000.00 Price / Sales684.90 Cash FlowN/A Price / CashN/A Book Value$2.66 per share Price / Book7.17 Profitability EPS (Most Recent Fiscal Year)($1.86) Net Income$-58,120,000.00 Net MarginsN/A Return on Equity-57.40% Return on Assets-52.21% Miscellaneous Employees37 Outstanding Shares32,700,000Market Cap$623.26 Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions What is Cara Therapeutics' stock symbol? Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA." How were Cara Therapeutics' earnings last quarter? Cara Therapeutics Inc (NASDAQ:CARA) released its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.04. View Cara Therapeutics' Earnings History. What price target have analysts set for CARA? 12 brokers have issued 1-year price targets for Cara Therapeutics' stock. Their forecasts range from $20.00 to $31.50. On average, they anticipate Cara Therapeutics' share price to reach $25.5769 in the next year. This suggests a possible upside of 34.2% from the stock's current price. View Analyst Ratings for Cara Therapeutics. What is the consensus analysts' recommendation for Cara Therapeutics? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Cara Therapeutics stock? Here are some recent quotes from research analysts about Cara Therapeutics stock: 1. HC Wainwright analysts commented, "We view this as a clear positive for the company, as it brings in minimally- dilutive financing ($50M cash plus $20M equity investment at $17/ share), validates our view on Korsuva, and de-risks the U.S. commercial launch. Despite the headline ex-US deal, we’re more focused on the new U.S. arrangement here because we don’t yet include ex-US in our model until we get more clarity on the regulatory and reimbursement landscape (our valuation is all-U.S.), and we assume the U.S. was also the primary value driver here for Vifor Fresenius as well. Vifor Fresenius is a JV of Vifor (VIFN:SW) and Fresenius Medical Care AG (FMS; not covered). We believe Vifor Fresenius is the best possible commercial partner for Cara, with Fresenius itself owning nearly 40% of U.S. dialysis centers." (5/23/2018) 2. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (3/21/2018) Who are some of Cara Therapeutics' key competitors? Some companies that are related to Cara Therapeutics include Spectrum Pharmaceuticals (SPPI), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), Arena Pharmaceuticals (ARNA), TESARO (TSRO), Global Blood Therapeutics (GBT), ACADIA Pharmaceuticals (ACAD), Zogenix (ZGNX), Myokardia (MYOK), Puma Biotechnology (PBYI), Phibro Animal Health (PAHC), Insmed (INSM), Prestige Brands (PBH) and PTC Therapeutics (PTCT). Who are Cara Therapeutics' key executives? Cara Therapeutics' management team includes the folowing people: Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 54)Dr. Frédérique Menzaghi Ph.D., Sr. VP of R&D (Age 52)Dr. Joseph Stauffer D.O., M.B.A., Chief Medical Officer (Age 52)Dr. Michael E. Lewis Ph.D., Co-Founder and Chief Scientific Advisor (Age 66)Dr. Mani Mohindru, Chief Financial Officer (Age 46) Has Cara Therapeutics been receiving favorable news coverage? Media headlines about CARA stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cara Therapeutics earned a media sentiment score of 0.15 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.64 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. Who are Cara Therapeutics' major shareholders? Cara Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Mesirow Financial Investment Management Inc. (0.07%), Cornerstone Wealth Management LLC (0.04%) and Exane Derivatives (0.02%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics. Which institutional investors are selling Cara Therapeutics stock? CARA stock was sold by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc.. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers and Frederique PhD Menzaghi. View Insider Buying and Selling for Cara Therapeutics. Which institutional investors are buying Cara Therapeutics stock? CARA stock was purchased by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC and Exane Derivatives. View Insider Buying and Selling for Cara Therapeutics. How do I buy shares of Cara Therapeutics? Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cara Therapeutics' stock price today? One share of CARA stock can currently be purchased for approximately $19.06. How big of a company is Cara Therapeutics? Cara Therapeutics has a market capitalization of $623.26 million and generates $910,000.00 in revenue each year. The biopharmaceutical company earns $-58,120,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Cara Therapeutics employs 37 workers across the globe. How can I contact Cara Therapeutics? Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700. MarketBeat Community Rating for Cara Therapeutics (NASDAQ CARA)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 459 (Vote Outperform)Underperform Votes: 208 (Vote Underperform)Total Votes: 667MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?